

# Chikungunya Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/C1350E7D6B83EN.html>

Date: August 2022

Pages: 111

Price: US\$ 2,000.00 (Single User License)

ID: C1350E7D6B83EN

## Abstracts

Chikungunya Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Drugs In Development, 2022, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected *Aedes aegypti* mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family *Togaviridae*. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1, 19 and 11 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 2, 7 and 3 molecules, respectively.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chikungunya Fever

(Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Global Markets Direct Report Coverage

Chikungunya Fever - Overview

Chikungunya Fever - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Chikungunya Fever - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chikungunya Fever - Companies Involved in Therapeutics Development

Chikungunya Fever - Drug Profiles

Chikungunya Fever - Dormant Projects

Chikungunya Fever - Product Development Milestones

Featured News & Press Releases

Jun 21, 2022: Emergent BioSolutions announces publication of CHIKV VLP phase 2 safety and immunogenicity data in The Lancet Infectious Diseases

Jun 09, 2022: Valneva to present on its single-shot chikungunya vaccine candidate, host symposium at NECTM8

May 26, 2022: Valneva concludes lot-to-lot Phase III trial of chikungunya vaccine

Mar 08, 2022: Valneva successfully completes pivotal phase 3 trial of single-shot chikungunya vaccine candidate

Feb 22, 2022: Emergex awarded ?490,525 UK aid grant by the Department of Health and Social Care to advance synthetic T cell vaccine candidate for chikungunya virus

Jan 31, 2022: Valneva announces initiation of adolescent phase 3 trial for its single-shot chikungunya vaccine candidate

Dec 21, 2021: Valneva announces positive lot-to-lot consistency trial results for its single-shot chikungunya vaccine candidate

Nov 15, 2021: Valneva to present its chikungunya vaccine candidate at the ASTMH 2021 Annual Meeting

Oct 18, 2021: Emergent commences Phase III trial of single-dose chikungunya vaccine

Sep 13, 2021: Peer-reviewed publication supports arthritic disease modifying effects of PPS in chikungunya virus

Aug 24, 2021: IVI and BBIL launch global Chikungunya vaccine phase II/III trial in Costa Rica

Aug 05, 2021: Valneva announces positive phase 3 pivotal results for its single-shot chikungunya vaccine candidate

Jul 07, 2021: Valneva awarded FDA breakthrough designation for its single-shot chikungunya vaccine candidate

Jul 05, 2021: Valneva to host symposium on Chikungunya vaccine candidate VLA-1553 at 31st European Congress of Clinical Microbiology & Infectious Diseases

Jun 10, 2021: Valneva completes recruitment for phase 3 lot-to-lot consistency trial of its Chikungunya Vaccine Candidate

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Chikungunya Fever, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Number of Products under Development by Universities/Institutes, 2022  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Universities/Institutes, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Chikungunya Fever - Dormant Projects, 2022  
Chikungunya Fever - Dormant Projects, 2022 (Contd..1)

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Chikungunya Fever, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Universities/Institutes, 2022  
Number of Products by Top 10 Targets, 2022  
Number of Products by Stage and Top 10 Targets, 2022  
Number of Products by Top 10 Mechanism of Actions, 2022  
Number of Products by Stage and Top 10 Mechanism of Actions, 2022  
Number of Products by Routes of Administration, 2022  
Number of Products by Stage and Routes of Administration, 2022  
Number of Products by Molecule Types, 2022  
Number of Products by Stage and Molecule Types, 2022



## I would like to order

Product name: Chikungunya Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/C1350E7D6B83EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C1350E7D6B83EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

